We are live on ! Find out more

Summit Therapeutics

SMMT

Market cap $13.8B

17.36 USD

+0.36

2.12%

At close Updated Sep 11, 12:56 PM EDT

1 day

2.12%

5 days

2.48%

1 month

14.81%

3 months

32.72%

6 months

7.96%

Year to date

-0.91%

1 year

-6.67%

5 years

175.12%

10 years

180%

About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Employees: 265

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 44.4%

Neutral 50%

Negative 5.6%

Zacks Investment Research

SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China

Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.

SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China

Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study

Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading higher on Thursday after its development partner, Akeso Inc., reported highly favorable overall survival data from a late-stage clinical trial.

Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study

November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet

Summit Therapeutics is positioned as a high-conviction buy into the November 2026 FDA PDUFA decision for ivonescimab in NSCLC. SMMT's ivonescimab demonstrates robust PFS and statistically significant OS benefits in multiple Phase III trials, supporting best-in-class potential versus PD-1 monotherapy. Financials reflect intentional capital deployment, with $690M+ cash and 4–5 quarters of runway to fund late-stage clinical catalysts and regulatory milestones.

November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression. HARMONi-2 (AK112-303) is a single-region, multi-center Phase III study conducted in China.

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

Zacks Investment Research

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade)

Summit Therapeutics, Inc. is upgraded to Buy as negative sentiment bottoms and catalysts approach, despite high volatility and cash burn. Ivonescimab demonstrated survival benefits in Chinese NSCLC and biliary tract cancer trials, with pivotal global data and FDA decisions pending. SMMT's liquidity covers 4–5 quarters, but aggressive pipeline expansion and high operating expenses raise going concern risks.

Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade)

Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy

Summit Therapeutics Inc. (NASDAQ:SMMT) partner Akeso Inc. on Wednesday released positive topline findings from its randomized Phase 3 HARMONi-GI1 clinical trial (or AK112-309).

Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). HARMONi-GI1 is a single-region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusi.

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients

Summit Therapeutics Inc. (NASDAQ:SMMT) announced that The Lancet Oncology published primary analysis results from its global Phase 3 HARMONi trial.

Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In HARMONi, ivonescimab in combination with platinum-doublet chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mu.

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

See News Rankings

Price charts implemented using Lightweight Charts™